LRRK2 and Parkinson disease: Healthy individuals carrying the LRRK2 p.G2019S mutation show increased levels of pro-inflammatory cytokines in serum and, in sporadic PD patients, LRRK2 levels are elevated in neutrophils, B-cells, T-cells, and CD16+ monocytes, when compared to healthy controls [53,54].